ART-27.13 is under clinical development by Artelo Biosciences and currently in Phase II for Cancer Anorexia-Cachexia Syndrome. According to GlobalData, Phase II drugs for Cancer Anorexia-Cachexia Syndrome does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ART-27.13 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ART-27.13 overview
ART-27.13 (NEO-1940, AZD-1940) is under development for the treatment of cancer related anorexia (weight loss) and cancer-related cachexia (muscle wasting). The drug candidate is a benzimidazole derivative which is administered through oral route. It acts by targeting cannabinoid (CB1) type 1 and type 2 receptor. The drug candidate is a new chemical entity.
See Also:
It was also under development for the treatment of post-operative pain, appetite loss, pain, nausea, vomiting, anxiety, insomnia in cancer patients, nociceptive pain, chronic low back pain and neuropathic pain.
Artelo Biosciences overview
Artelo Biosciences is a biopharmaceutical company. The company develops and commercializes proprietary therapeutics targeting the endocannabinoid system.
For a complete picture of ART-27.13’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
